Abstract: A novel therapeutic agent and novel anti-HTLV-1 drug for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is provided. A substance capable of inhibiting tyrosine kinase encoded by the ABL1 gene is contained as an active ingredient.

Abstract: A peptide or a salt thereof having an amino acid sequence represented by (a) or (b) shown below having a promotive effect on a proliferation of fibroblast cells, a composition for enhancing proliferation of fibroblast cells containing one or more of them, a composition for enhancing elastin production in fibroblast cells containing one or more peptides or salts thereof having an amino acid sequence represented by (a), (b) or (c) shown below and a composition for enhancing elastin production in chondrocytes containing one or more peptides or salts thereof having an amino acid sequence represented by (c) shown below.

Abstract: AD conversion is performed by using a combination of a parallel AD converter that includes a plurality of comparators to compare an input potential of an analog input signal sampled by a track and hold circuit and reference potentials different from one another and determines a value of a predetermined number of bits on the higher-order side of a digital signal and a single-slope AD converter that reduces the input potential of the analog input signal sampled by the track and hold circuit at a constant speed, converts a time taken until the reduced input potential becomes equal to a reference potential corresponding to the value determined by the parallel AD converter to a digital value, and determines a remaining value on the lower-order side of the digital signal, and thereby the number of bits of the single-slope AD converter can be reduced and high-speed AD conversion is enabled with a small area and low power consumption.

Abstract: This invention relates to an IgG-binding peptide, an IgG-binding peptide modified with a cross-linking agent, a conjugate of the IgG-binding peptide modified with a cross-linking agent and IgG, and a method for producing the conjugate, etc.

Abstract: It is an object of the present invention to provide a novel therapeutic agent for hepatoma viruses. Specifically, the present invention relates to an anti-hepatoma virus agent, containing as an active ingredient a compound represented by the following Formula (I) or a pharmaceutically acceptable salt thereof: (wherein R1 is fluorine or hydrogen).

Abstract: A noninvasive method for early detection of a precancerous lesion that may be developed into oral cancer by large-scale screening is provided. The method is a method for obtaining data for diagnosis of an oral precancerous lesion in a subject by detecting methylation of DNA in gargled fluid collected from the subject, wherein the DNA is DNA in a promoter region of at least one gene selected from the following group of genes: RASSF1, DAPK1, CD44, BRCA2, FHIT, CDKN2A, HIC1, CASP8, RAR?, CDKN2B, CHFR, ATM, CDKN1B, BRCA1, and CADM1.

Abstract: [Problem] To provide a novel and effective method for treating cancer, method for preventing cancer, and method for suppressing metastasis by targeting cancer stem cells, the methods being capable of labeling and damaging cancer stem cells; and to provide a method for damaging and a method for identifying cancer stem cells. [Solution] The present invention provides a viral vector having a promoter that is specifically expressed in cancer stem cells and that can be used for treatment and diagnosis. Furthermore, the present invention provides a method for treating cancer, a method for preventing cancer, and a method for suppressing metastasis using this viral vector, and further provides a method for damaging and a method for identifying cancer stem cells. Furthermore, the present invention provides a labeling agent and a toxic agent for cancer stem cells containing the vector as the active ingredient, and further provides a diagnostic drug, a therapeutic drug, and a metastasis suppressant for cancer.

Abstract: The present invention provides a method for detection of a basic peptide by mixing a sample suspected to contain the basic peptide and a reagent containing denatured albumin and detecting turbidness due to a complex of the basic peptide and denatured albumin.

Abstract: A vibration damping device 20 includes: a crank member 22 that is coupled to a driven member 15 via a first coupling shaft A1 and that is swingable about the first coupling shaft A1 along with rotation of the driven member 15; and an inertial mass body 24 that is coupled to the driven member 15 via the crank member 22 and a connecting rod 23 and that is swung about a center of rotation RC in conjunction with the crank member 22 along with rotation of the driven member 15. A component force of a centrifugal force that acts on the crank member 22 along with rotation of the driven member 15 in a direction that is orthogonal to the direction from the center of the first coupling shaft A1 toward the center of gravity G always acts on the crank member 22 as a restoring force that acts to return the inertial mass body 24 to the center of the swing range. The component force is maximum when the inertial mass body 24 is positioned at the center of the swing range.

Abstract: This invention relates to an IgG-binding peptide, an IgG-binding peptide modified with a cross-linking agent, a conjugate of the IgG-binding peptide modified with a cross-linking agent and IgG, and a method for producing the conjugate, etc.

Abstract: The present invention relates to an agent for killing HIV-1-infected cells, comprising a compound represented by formula (I): wherein Ar1 and Ar2 are the same or different and represent a substituted or unsubstituted aromatic group, and X represents —CH2O— or —CH?CH—, its salt, or their solvate, and a combined preparation for simultaneous, separate, or sequential administration in treating or preventing HIV-1 infection, comprising two separate preparations: (a) a preparation comprising a compound represented by the formula (I), its salt, or their solvate, and (b) a preparation comprising an anti-HIV-1 drug.

Abstract: An observation and photography apparatus that has a polishing mechanism attached thereto. The polishing mechanism is provided with a turntable with a perpendicular rotation shaft, a polishing cloth for polishing the surface of a sample attached to the bottom surface of the turntable, and a polishing-fluid spraying nozzle disposed below the polishing cloth for spraying polishing fluid containing polishing material upward to we the polishing cloth.

Abstract: Provided is a pain-related compound, a pain-related pharmaceutical composition, and use of the same. Provided in one or more embodiments is a compound represented by Formula (I), a prodrug of the same, or a pharmaceutically permissible salt of any of the same.

Abstract: According to this invention, the following are provided: a pharmaceutical composition for treating and/or preventing esophageal stenosis, comprising an HGF protein as an active ingredient (wherein the HGF protein may be a polypeptide that is any one of the following: (a) a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 2; (b) a polypeptide comprising an amino acid sequence shown in SEQ ID NO: 2 in which one to several amino acids are deleted, substituted, or added; or (c) a polypeptide comprising an amino acid sequence having at least 90% identity with the amino acid sequence shown in SEQ ID NO: 2; and a stent comprising the pharmaceutical composition.

Abstract: Techniques are provided in which a “dichromat” (e.g., a color-blind person) is able to identify the hue of an object without determining the color difference signals that are applied to the original color image. Such features may be implemented by performing hue rotation processing on each pixel data of the original color image captured.

Abstract: A high-density shape reconstruction is conducted in measuring animal bodies as well. An image processing system has a projection device, an imaging device, and an image processing apparatus connected to the projection device and the imaging device, wherein the projection device projects a projected pattern to an observation target, the imaging device captures the projected pattern, and the image processing apparatus performs shape reconstruction based on an input image including the projected pattern. The image processing apparatus includes a unit for fetching the input image captured by the imaging device and performing line detection for the projected pattern projected by the projection device, wherein the projected pattern is a grid pattern formed of wave lines; and a unit for performing shape reconstruction by associating intersection points of vertical and horizontal lines extracted by the line detection with the projected pattern.

Abstract: The present invention provides a method for detection of a basic peptide by mixing a sample suspected to contain the basic peptide and a reagent containing denatured albumin and detecting turbidness due to a complex of the basic peptide and denatured albumin.

Abstract: This invention relates to: a peptide which comprises an amino acid sequence consisting of 12 to 18 amino acid residues represented by (X1-3)—C—(X8-10)—C—(X1-3) wherein each X independently represents an arbitrary amino acid residue other than cysteine, and C represents a cysteine residue, and is capable of binding to human IgA; and to a method for analyzing or purifying human IgA using the peptide.

Abstract: The present invention relates to a detection method for a genetic disease, and specifically relates to detection of disease-causing genes for autosomal recessive inherited Charcot-Marie-Tooth disease (CMT). In the method according to the present invention, a mutation(s) in MME (membrane metallo-endopeptidase) gene, FAT3 (FAT tumor suppressor homolog 3) gene, and/or SELRC1 (Sell repeat containing 1) gene in a biological sample are/is detected.

Abstract: Provided is a pain-related compound, a pain-related pharmaceutical composition, and use of the same. Provided in one or more embodiments is a compound represented by Formula (I), a prodrug of the same, or a pharmaceutically permissible salt of any of the same.